Browse All Grants
20,252 grants found
Showing 581 – 600 of 20,252 grants
Administrative Core
CORE 1 – ADMINISTRATIVE CORE: SUMMARY The overall goal of this P01 program project grant (PPG) application, titled ELEVATE, is to evaluate novel therapeutic approaches for hepatoce...
Bile Acid-Mediated Signaling In HCC
PROJECT 1: SUMMARY Hepatocellular cancer (HCC) is a rising cause of cancer-related mortality. Nonalcoholic fatty liver disease (NAFLD), especially its aggressive form, nonalcoholic...
Cooperation of Co-Amplified Genes in Hepatocellular Carcinoma
PROJECT 2: SUMMARY Hepatocellular carcinoma (HCC) is a highly fatal disease with an alarming increase in incidence and mortality. Obesity-induced non-alcoholic steatohepatitis (NAS...
A Novel Target in The Tumor Myeloid Compartment for Hepatocellular Carcinoma
PROJECT 3: SUMMARY Given the limited clinical benefits of the current treatments for hepatocellular carcinoma (HCC), there is an urgent need for novel approaches to improve patient...
Designer Cytokine Therapy of Hepatocellular Carcinoma
PROJECT 4: SUMMARY Innovative therapeutic strategies are warranted to treat hepatocellular carcinoma (HCC), which is one of the most common malignancies worldwide with current appr...
Mouse Model and Pathological Analysis Core
CORE 2 - MOUSE MODELS AND PATHOLOGICAL ANALYSIS CORE: SUMMARY The purpose of Core 2 is to support the research of each of the projects in the ELEVATE program project grant (PPG) by...
Biostatistics and Bioinformatics Core (BBC)
CORE 3 - BIOSTATISTICS AND BIOINFORMATICS CORE: SUMMARY The overarching goal of the ELEVATE program project grant (PPG) is to leverage molecular abnormalities in hepatocellular car...
Antibody bound bacteria during HPV infection and cervical dysplasia
PROJECT SUMMARY High-risk human papillomavirus (HR-HPV) is a known cause of >95% of cervical cancer and cervical intraepithelial neoplasia (CIN). Prophylactic vaccines are avail...
Precision Tumor Sampling of Melanoma Using Laser Microbiopsy
ABSTRACT Melanoma is the fifth most common cancer in the US with almost 100,000 cases estimated for 2023. Late-stage disease has a five-year survival of just 30%, resulting in almo...
The Young Empowered Scientists for ContinUed Research Engagement (YES for CURE) Program at the Dana-Farber/Harvard Cancer Center (DF/HCC)
YES for CURE Project Summary Increasing the participation and retention of underrepresented minorities in cancer-related STEM fields is critical for eliminating cancer disparities...
Paradigm Shift in the Management of Patients with Previously Untreated Chronic Lymphocytic Leukemia through NCI-sponsored Clinical Trials
PROJECT SUMMARY Dr. Parikh is a consultant in the Division of Hematology, Department of Medicine at Mayo Clinic in Rochester, MN, and holds the rank of Associate Professor of Medic...
Targeting the tumor microenvironment with engineered CD4+ T cells
Abstract Novel immune therapies are needed to help the majority of patients with melanoma and other solid tumors who fail to benefit or stop responding to immune checkpoint inhibit...
Understanding the pathogenesis of classic Hodgkin lymphoma in persons living with HIV through conventional and spatial transcriptomics
PROJECT SUMMARY/ABSTRACT The incidence of hematological malignancies is higher in persons living with PLWH (Persons living with HIV (Human Immunodeficiency Virus)). The risk of dev...
Targeting proton-sensing GPR68 as a ferroptosis-based therapy for glioblastoma
Glioblastoma (GBM) is the most common primary brain cancer in adults. Over 10,000 people are estimated to die yearly from GBM despite aggressive treatment, and there has been no su...
Increasing Access and Participation to Early Phase Clinical Trials to the Underrepresented Populations
Project Summary Access to health care including clinical trials leading to paradigm-changing cancer treatments is critical for high quality cancer care and equity in society. Diffe...
Combination metabolic therapy for diffuse midline glioma
PROJECT SUMMARY Diffuse midline gliomas (DMGs) are devastating primary brain tumors in children. Patient prognosis is abysmal with median survival of ~9 months after initial diagno...
Assessment of a recently developed boron-based HIF inhibitor as a prospective therapy for renal cell carcinoma (RCC)
Inactivation of the VHL tumor suppressor protein (pVHL) is frequently observed in clear cell Renal Cell Carcinoma (RCC). The mutated pVHL does not bind and degrade the regulatory α...
PRecision IMaging to Evaluate Kaposi Sarcoma (PRIME-KS)
ABSTRACT Monitoring treatment response for Kaposi sarcoma (KS) using present clinical judgement is inadequate. While objective monitoring of KS lesions can be performed, the measur...
Rewiring T cell exhaustion with immune checkpoint blockade therapy
PROJECT SUMMARY The goal of this project is to determine whether it is possible to promote the development and/or maintenance of CD8+ T cells that are essential for anti-tumor resp...
New Von Hippel Lindau (VHL) tumor suppressor signaling in renal cancer
Project Summary Clear cell renal cell carcinoma (ccRCC), which accounts for approximately 85% of all renal cancers, is resistant to a variety of cancer therapies and is highly leth...